

DOCKET NO. 9511-057-27 DIV

RECEIVED

SEP 19 2001

TECH CENTER 1600/2900

#8  
YC  
9-19-01

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**


IN RE APPLICATION OF: Richard J. BUCALA, et al.

ART UNIT: 1644

SERIAL NO.: 09/557,823

EXAMINER: P. Nolan

FILING DATE: April 25, 2000



INHIBITION OF MIGRATION INHIBITORY FACTOR IN THE  
TREATMENT OF DISEASES INVOLVING CYTOKINE-MEDIATED  
TOXICITY

**RESPONSE TO RESTRICTION REQUIREMENT**

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

In response to the Restriction Requirement dated June 28, 2001, Applicants elect Group I, Claims 66-68, for further prosecution on the merits. This election herein is being made with traverse.

**REMARKS**

The Examiner has required restriction in the above-identified application as follows:

Group I, Claims 66-68 drawn to a diagnostic method with an anti-MIF antibody, classified in class 435, subclass 7.1; or

Group II, Claims 69-72 drawn to a pharmaceutical composition comprising anti-MIF antibody and a kit comprising said antibody, classified in class 424, subclass 145.1.

Applicants elect Group I, Claims 66-68, with traverse. Applicants respectfully traverse on the ground that the Claim 69, included in Group II, is directed to a diagnostic kit comprising an antibody and other reagents for carrying out the diagnostic methods of Claims 66-68, in Group I, not to a kit comprising a therapeutic antibody or pharmaceutical